Not sure how you can assume one large pharma would develop more indications all at once vs NEU licensing out to multiple. The assumption is a dangerous one given pharma delay developing indications all the time, just look at Acadia and FragileX. A single company still has finite human resources required to progress these, regardless of MC.
Share Price, page-8573
-
- There are more pages in this discussion • 3,164 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.56 |
Change
-0.360(2.59%) |
Mkt cap ! $1.733B | |||
| Open | High | Low | Value | Volume |
| $13.94 | $13.96 | $13.50 | $6.421M | 470.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1643 | $13.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.61 | 3100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |